Business
Vera Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ: VERA), a clinical-stage biotechnology company focused on
About this update from Vera Therapeutics, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that management will provide a corporate presentation and participate in one-on-one investor meetings at the Jefferies Virtual Healthcare Conference, which is taking place June 1-4, 2021. Presentation details: Date:Friday, June 4, 2021Time:9:00 AM PT (12:00 PM ET)Presenter:Marshall Fordyce, MD, CEO and Founder of Vera A live webcast of the presentation can be accessed by visiting the investor relations section of the Company’s website, www.veratx.com. A replay of the webcast will also be available and archived on the site for 90 days following the presentation date. About Vera TherapeuticsVera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera’s lead program is atacicept, a fusion protein that is in development for IgA nephropathy, a disease with high unmet medical need and no approved therapies. In addition, Vera is evaluating additional diseases where atacicept’s reduction of autoantibodies may prove medically useful, including lupus nephritis (LN), a severe renal manifestation of systemic lupus erythematosus (SLE). For more information please visit www.veratx.com. Investor Contact:[email protected] Media Contact:Greig Communications, Inc.Kathy Vincent(310) [email protected] \nSource: Vera Therapeutics","length":3536,"tagName":"div"}]